SQZ Biotech (SQZ), a Boston, MA-based developer of a platform that enables a variety of materials to enter a cell, raised $5m in Series A funding.
The round was led by Polaris Partners with participation from 20/20 Healthcare Partners and others.
The company intends to use the funds for further development of the platform and exploration of clinical indications enabled by the technology’s cell engineering capabilities.
Discovered by Massachusetts Institute of Technology (MIT) professors Drs. Klavs Jensen, Robert Langer, and Armon Sharei, cell squeeze technology is a microfluidic chip that enables the delivery of materials into almost any cell type, including primary human-derived cells. SQZ maintains the exclusive worldwide license from MIT for CellSqueeze for any application.
Dr. Sharei, serves as Chief Executive Officer of SQZ.